Navigation Links
Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics
Date:1/3/2012

LOS ANGELES, Jan. 3, 2012 /PRNewswire/ -- TSH testing, the gold standard in hypothyroid diagnosis, may be misleading according to the studies quoted in a new article titled Hormone Replacement Therapy in the Geriatric Patient: Current State of the Evidence and Questions for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone Augmentation in Geriatric Clinical Practice. The article, independently written and published, is a broad study of hormone replacement in geriatric patients. In the thyroid section, written by Kent Holtorf M.D., it details the difference between serum thyroid hormone levels and tissue thyroid hormone levels, particularly in cases of chronic and acute stress.

According to the study models presented in the article, physiological stress, caused by aging or illness, means patients can present with typical hypothyroid symptoms but with serum testing that shows normal TSH and even T3. "As a result, when relying on serum tests only, clinicians do not treat patients presenting with this thyroid picture assuming they are euthyroid," reads the article. However, those same patients may be experiencing diminished T3 levels within the peripheral tissues, due to reactive changes at the cellular level. According to the authors, this leaves "a gaping hole" and misses "the opportunity to help the patients' condition."

The article also addresses the possible benefits of marking reverse T3 levels in serum testing as a means of determining the overall health of the "hypothalamic–pituitary–thyroid– cellular axis," and it warns of the suppression of TSH serum levels in some patients with nonthyroidal illness or who are on medication. This kind of "confusion" only serves to undermine further the reliability of standard thyroid testing.

The article concludes with a summary of treatment options, citing T3 preparations as more effective in cases of chronic or age-related stress. "Many symptomatic patients with low tissue thyroid levels with normal TSH and T4 levels may benefit from T3 thyroid replacement, often with significant improvement in fatigue, depression, weight gain and obesity, heart failure, fibromyalgia, cholesterol levels, and numerous other chronic conditions." Additionally, some of the long-held fears of significant side effects associated with hormone supplementation may be overstated.

KENT HOLTORF, MD: Dr. Holtorf is the founding director of the Bioidentical Hormone Initiative as well as the National Academy of Hypothyroidism  and the medical director of the Holtorf Medical Group, Center for Hormone Imbalance, Hypothyroidism, and Fatigue, located in Los Angeles, Pasadena and Foster City, CA and Philadelphia, PA. He founded the Holtorf Medical Group in 2001 and continues to treat patients from across the country and abroad. His full profile can be viewed at www.holtorfmed.com

CONTACT: Jeny Kherkher, +1-310-375-2705, jenyk@holtorfmed.com


 


'/>"/>
SOURCE Holtorf Medical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
2. Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
3. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
4. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
5. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
6. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
7. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
8. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
9. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
10. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
11. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- The ALS Association, in partnership with ALS Finding a Cure, ... biomarker to track TDP43 aggregation. The successful team(s) with the ... investment. --> --> ... in the brain and the spinal cord. Eventually, people with ... which often leads to total paralysis and death within two ...
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... SPRINGS, Florida , February 10, 2016 ... Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. ... Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... --> Today,s latest Orphan Drug Designations become vitally ... by the FDA to novel drugs and biologics which are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... AxoGen, ... market, will report results for the fourth quarter and full year ended December 31, ... host a conference call and webcast for the investment community following the release at ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 ... "Better with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis ... book’s publication date is March 16, 2016. A free review copy is available ...
Breaking Medicine News(10 mins):